G1 Therapeutics, Inc. Common Stock

GTHX

Market cap $377M

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating G1 Therapeutics, Inc. ( Nasdaq: GTHX ) , relating to its proposed merger with Kahn Swick & Foti, LLC (“KSF”). Under the terms of the proposal, KSF will commence a tender offer to purchase GTHX stock at a price of $7.15 per share.

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

G1 Therapeutics (GTHX) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.14 per share a year ago.

- Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 - - Achieved $15.8 Million in Net Revenue from Sales of COSELA® (trilaciclib) - - Drove Double Digit Quarter-Over-Quarter Growth in COSELA Vial Volume and Net Revenue - - Reaffirmed 2024 Net COSELA Revenue Guidance of Between $60 and $70 Million - - Due to the Pending Transaction with Pharmacosmos, G1 will Not Host a Conference Call and Webcast to Discuss the Second Quarter Financial Results and Business Update - RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2024.

MILWAUKEE , Aug. 7, 2024 /PRNewswire/ -- Ademi LLP is investigating GI (Nasdaq: GTHX) for possible breaches of fiduciary duty and other violations of law in its transaction with Pharmacosmos. Click here to learn how to join our investigation https://www.ademilaw.com/case/g1-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of G1 Therapeutics, Inc. (NASDAQ: GTHX) to Pharmacosmos A/S for $7.15 per share in cash is fair to G1 shareholders. Halper Sadeh encourages G1 shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether G1 and its board of di.

G1 Therapeutics (NASDAQ: GTHX ) stock is rocketing higher on Wednesday after the company announced an acquisition deal with Pharmacosmos Group. Pharmacosmos Group has agreed to acquire all outstanding shares of GTHX stock for $7.15 in cash.

- Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - Pharmacosmos' Significant Resources and Expertise in Hematology and Supportive Care to Maximize Availability of COSELA for Patients with ES-SCLC - - Transaction Expands and Strengthens Pharmacosmos' Global Commercial Portfolio - - G1's Shareholders to Receive U.S. $7.15 per Share in Cash for a Total Equity Value of Approximately $405 Million - RESEARCH TRIANGLE PARK, N.C. and HOLBAEK, Denmark, Aug. 07, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, and Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, today announced that they have entered into a definitive merger agreement under which Pharmacosmos A/S, through its U.S. subsidiary Pharmacosmos Therapeutics Inc., will acquire all outstanding shares of G1 Therapeutics common stock for U.S. $7.15 per share in cash for a total equity value of approximately $405 million, which represents a 68% premium to G1's closing share price on August 6, 2024 and a 133% premium to G1's prior 30-day volume weighted average price.

RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 12,300 shares of G1's common stock and 6,150 restricted stock units (RSUs) to five hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).